DGAP-News

MOLOGEN AG: Immunological data on renal cancer therapy MGN1601 presented at CIMT

DGAP-News: MOLOGEN AG / Key word(s): Study
MOLOGEN AG: Immunological data on renal cancer therapy MGN1601
presented at CIMT

07.05.2014 / 07:30

---------------------------------------------------------------------

MOLOGEN AG: Immunological data on renal cancer therapy MGN1601 presented at
CIMT

- Activation of the immune system after treatment with MGN1601 observed

- Favorable safety and tolerability profile

- Promising median overall survival data in a subgroup of patients

Berlin, May 7, 2014 - MOLOGEN AG announced today that further immunological
data from the phase I/II ASET renal cancer study with MGN1601 have been
presented in a poster at the 12th CIMT Annual Meeting (The Association for
Cancer Immunotherapy) in Mainz, Germany. The activation of the immune
system after treatment with the tumor cell-based cancer vaccine MGN1601
reflects the expected mode-of-action and was supported by the immunological
findings. Furthermore, a good safety profile and promising median overall
survival data in a subgroup of patients were demonstrated. One patient
remained up to 48 weeks with stable disease and another patient achieved a
long-term partial response of more than 120 weeks.

In the trial 19 heavily pretreated patients with advanced renal cancer were
enrolled to assess safety, tolerability and immunological effects of
MGN1601. The evaluation of T-cell responses in subgroups of patients showed
first evidence of cytotoxic antitumor immune response after MGN1601
vaccination. Moreover, significant improvement of the cellular immune
function during the course of the treatment was observed.

The coordinating study investigator of the ASET trial PD Dr. Viktor
Grünwald, Medical School Hannover, Clinic for Hematology, Hemostasis,
Oncology and Stem Cell Transplantation, commented: "These results exceeded
our expectations. In particular, I am especially impressed by one of my
patients who is being treated for more than 30 months and is still
progression-free. At the same time we see that MGN1601 is safe and well
tolerated. I look forward to participating in the future development
program of this promising drug candidate."

The monotherapy with tumor cell-based cancer vaccine MGN1601 was well
tolerated and safe. Furthermore, treatment with MGN1601 resulted in
promising median overall survival of 115.3 weeks in a subgroup of patients
who completed the study per protocol. Overall, two patients achieved
prolonged disease control. One patient with stable disease eventually